iMediSync

iMediSync operates at the intersection of digital mental healthcare, EEG diagnostics, wearable medical devices, and neurostimulation. Its differentiation is the combination of a 19-channel wireless dry-EEG system, cloud-based quantitative EEG analysis, HRV measurement, and near-infrared photobiomodulation in a connected care workflow. The company also describes age- and gender-specific normative comparisons, automated artifact rejection, 3D brain mapping, and source-level analysis, giving it a broader stack than a standalone EEG hardware vendor or a general-purpose digital mental-health application. Competitive pressure is likely to come from established neurodiagnostic device manufacturers, quantitative EEG software providers, consumer neurotechnology brands, and digital therapeutics companies. iMediSync’s product breadth may support differentiation in clinics seeking assessment and intervention in one workflow, but it also creates execution requirements across hardware validation, clinical evidence, regulatory approvals, data privacy, and provider adoption. With Series C as its latest disclosed stage and $13.2 million in total funding, the company appears to be an early commercial-stage specialist rather than a scaled category leader.

iMediSync was founded on Dec 18, 2012 and built its trajectory through six disclosed funding rounds between 2016 and 2022. The financing sequence progressed from two Seed rounds to two Series A rounds in March and July 2018, a $4.1 million Series B in 2020, and a $6.3 million Series C on Jan 27, 2022. The structured funding total is $13.2 million, with KDB Bank Europe identified as the Series B lead investor. Product expansion has been a central inflection point: iSyncWave combines wireless dry EEG with photobiomodulation, while iSyncBrain, iSyncHeart, and iSyncMe extend the platform into cognitive screening, HRV-based emotional monitoring, and lighter-weight neurotherapy. Hiring activity reported in early 2023 targeted deep-learning and machine-learning researchers alongside frontend and backend developers, indicating investment in both clinical algorithms and product infrastructure. Patent activity continued in 2025 across EEG measurement, digital phenotyping, and brainwave-based therapy.